Clinical Trials Browser

Adenocarcinoma, Adenoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT00226811 2015-03-30

An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

Phase 2 Completed

78 enrolled 14 charts

Gastrointestinal

Stomach Neoplasms

NCT01215565 2014-03-13

Fibrolam

Phase 2 Terminated

4 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pathologic Processes

NCT00397787 2013-06-04

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Phase 2 Completed

64 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01238055 2013-04-09

Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

Phase 2 Completed

116 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT00609622 2012-10-11

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Phase 2 Terminated

191 enrolled 10 charts

Gastrointestinal

Colorectal Neoplasms

NCT00400569 2012-08-28

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Phase 2 Completed

48 enrolled 9 charts

GastrointestinalSarcoma

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous

NCT00514228 2012-06-26

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

45 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00495625 2012-03-27

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Phase 2 Terminated

33 enrolled 11 charts

Gastrointestinal

Liver Neoplasms

NCT00967603 2012-02-01

PACT-12

Phase 2 Completed

56 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00673504 2011-12-01

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Phase 2 Completed

105 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00668863 2011-10-17

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Phase 2 Completed

71 enrolled 20 charts

Gastrointestinal

Colorectal Neoplasms

NCT00247676 2010-02-18

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

Phase 2 Completed

37 enrolled 30 charts

Gastrointestinal

Liver Neoplasms

NCT00137449 2009-09-15

Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor

Phase 2 Completed

60 enrolled 19 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00077987 2007-01-11

Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.

Phase 2 Completed

84 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Sunitinib and Capecitabine for First Line Colon Cancer

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

RESUNET

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Sutent + Taxol for Advanced Esophageal Cancer

SUN-CK

Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors

NET

An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

Fibrolam

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

PACT-12

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor

Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.